Fei Zhou

13PUBLICATIONS
24CO-AUTHORS
Predictive and prognostic markersMolecular targetsCancer diagnosisCancer therapy (excl. chemotherapy and radiation therapy)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (13)

|Sep 07, 2026
Clinical utility of molecular residual disease detection in early-stage resected EGFR-mutated non-small cell lung cancer.

|Apr 17, 2026
ELMO2 is a therapeutic vulnerability in mesenchymal-like and drug-resistant non-small cell lung cancer.

|Nov 14, 2025
Cost-effectiveness of PD-L1 testing to guide immunotherapy for patients with advanced non-small-cell lung cancer in China.

Fei Zhou, Yuan Li, Jian Ming

|Nov 11, 2025
Navigating the landscape of EGFR TKI resistance in EGFR-mutant NSCLC - mechanisms and evolving treatment approaches.

Jing Zhao, Wanting Xu, Fei Zhou

|Nov 29, 2024
The changing treatment landscape of EGFR-mutant non-small-cell lung cancer.

Fei Zhou, Haoyue Guo, Yang Xia

|Nov 03, 2024
First-in-human, phase 1 dose-escalation and dose-expansion study of a RET inhibitor SY-5007 in patients with advanced RET-altered solid tumors.

Wei Li, Yongsheng Wang, Anwen Xiong

Pageof 3

Frequent Collaborators

4 joint publications

Caicun Zhou

2 joint publications

Xiuning Le

1 joint publications

Xing Li

1 joint publications

Caicun Zhou